GeoVax to Showcase COVID-19 Vaccine and Cancer Therapy Research at Prominent Medical Conferences

GeoVax Labs is set to present significant clinical research at two prestigious medical conferences in April 2025, showcasing innovative approaches to COVID-19 vaccination and cancer therapy. The presentations will provide insights into the company's advanced therapeutic strategies targeting critical healthcare challenges.

At the World Vaccine Congress in Washington, DC, Dr. Don J. Diamond from the City of Hope Comprehensive Cancer Center will discuss Phase 2b study results for GeoVax's multi-antigen COVID-19 vaccine candidate, GEO-CM04S1. The presentation will focus on comparative evaluations with currently approved COVID-19 vaccines, potentially offering new solutions for immunocompromised patients.

The research aims to address limitations in existing vaccine technologies, particularly for patient populations with complex medical conditions such as hematologic cancers. By developing a vaccine with potentially enhanced effectiveness, GeoVax could provide critical medical advancements for vulnerable patient groups who have limited protection from current vaccination protocols.

During the American Association of Cancer Research conference in Chicago, Dr. J. Marc Pipas will present findings on Gedeptin, a viral-vectored gene-directed prodrug therapy targeting solid tumors. This innovative approach represents a potential breakthrough in oncological treatment, specifically addressing needle-accessible solid tumors.

The Gedeptin program, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, demonstrates GeoVax's commitment to developing novel therapeutic strategies. The research could potentially offer new treatment options for patients with challenging cancer diagnoses.

These conference presentations underscore GeoVax's ongoing efforts to develop cutting-edge medical technologies. By focusing on both infectious diseases and oncological treatments, the company is positioning itself at the forefront of biomedical innovation, addressing critical healthcare needs through advanced research and development.